Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Custodio AB et al. - Patients with early stage NSCLC are at substantial risk for recurrence even after potentially curative surgical resection, and adjuvant chemotherapy. The current staging system is inadequate for predicting the outcome of treatment and the prognosis in an individual patient. Molecular markers may provide additional information about the likelihood of relapse beyond that obtained from pathologic staging. They may also have value in determining which patients will benefit from adjuvant platinum-based chemotherapy. This review focuses on:

  • Additional studies will be required to determine whether these markers are useful in selecting pts for adjuvant platinum based chemotherapy

    Today in Basic Science/Genetics...keeping you current

    Thrombopoietin in normal and neoplastic stem cell development
    Best Practice & Research: Clinical Haematology , 12/07/09

    Mechanisms of mutations in myeloproliferative neoplasms
    Best Practice & Research: Clinical Haematology , 12/07/09

    Ursodeoxycholic acid switches oxaliplatin-induced necrosis to apoptosis by inhibiting reactive oxygen species production and activating p53-caspase 8 pathway in HepG2 hepatocellular carcinoma
    International Journal of Cancer, 12/07/09


    Sponsor
  • Article Search

    Keyword:

    Search:

    Published within

    Sort By:
    Date
    Relevance


    Sponsor

    Sponsor

    Send this Summary to a Colleague

    Enter email address